Product Information
GS IBUPROFEN 100 MG CHEW TAB is a generic product labeled by L. Perrigo Company, priced at $0.1544 per EA under NDC 00113246162. Its NADAC has been published 283 times since May 5, 2021.
FDA first approved this application on Jan 16, 2004.
Strength
100 mg/1
Manufacturer
L. Perrigo CompanyNDC
00113246162
Classification
Generic
Dosage Form
TABLET, CHEWABLE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA076359FDA Approved
1/16/2004
On Market Since
10/9/2019
Pharmacological Classes
Price Statistics
The NADAC for GS IBUPROFEN 100 MG CHEW TAB has been published 283 times since May 5, 2021, and over the history we have for it it has risen 16.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1544 per EA |
|---|---|
| All-time high | $0.1554 (May 13, 2026) |
| All-time low | $0.1317 (Oct 20, 2021) |
| 52-week high | $0.1554 |
| 52-week low | $0.1393 |
| Median price | $0.1397 |
| Average price | $0.1410 |
| Largest weekly change | -9.2% (Jul 19, 2023) |
| Weeks tracked | 283 |
| Tracking since | May 5, 2021 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS IBUPROFEN 100 MG CHEW TAB?
The current National Average Drug Acquisition Cost (NADAC) for GS IBUPROFEN 100 MG CHEW TAB, manufactured by L. Perrigo Company, is $0.1544 per EA (NDC 00113246162), effective Sep 30, 2026.
How has the price of GS IBUPROFEN 100 MG CHEW TAB changed over time?
Over the history we have for it, the NADAC for GS IBUPROFEN 100 MG CHEW TAB has risen 16.0%. It has been tracked across 283 weekly CMS publications since May 5, 2021.
What are the highest and lowest recorded NADAC prices for GS IBUPROFEN 100 MG CHEW TAB?
Since May 5, 2021, the NADAC for GS IBUPROFEN 100 MG CHEW TAB has ranged from a low of $0.1317 (Oct 20, 2021) to a high of $0.1554 (May 13, 2026), with a median of $0.1397 per EA.
Are there cheaper alternatives to GS IBUPROFEN 100 MG CHEW TAB?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GS IBUPROFEN 100 MG CHEW TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures GS IBUPROFEN 100 MG CHEW TAB?
GS IBUPROFEN 100 MG CHEW TAB (NDC 00113246162) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.